Thomason MJ - Search Results

1

Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial.

Mallewa J, Szubert AJ, Mugyenyi P, Chidziva E, Thomason MJ, Chepkorir P, Abongomera G, Baleeta K, Etyang A, Warambwa C, Melly B, Mudzingwa S, Kelly C, Agutu C, Wilkes H, Nkomani S, Musiime V, Lugemwa A, Pett SL, Bwakura-Dangarembizi M, Prendergast AJ, Gibb DM, Walker AS, Berkley JA; REALITY trial team. Mallewa J, et al. Among authors: thomason mj. Lancet HIV. 2018 May;5(5):e231-e240. doi: 10.1016/S2352-3018(18)30038-9. Epub 2018 Apr 10. Lancet HIV. 2018. PMID: 29653915 Free PMC article. Clinical Trial.

2

Limited sampling models to predict the pharmacokinetics of nevirapine, stavudine, and lamivudine in HIV-infected children treated with pediatric fixed-dose combination tablets.

Burger D, Ewings F, Kabamba D, L'homme R, Mulenga V, Kankasa C, Thomason M, Gibb DM, Chintu C, Walker AS. Burger D, et al. Ther Drug Monit. 2010 Jun;32(3):369-72. doi: 10.1097/FTD.0b013e3181d75e47. Ther Drug Monit. 2010. PMID: 20386361

3

Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial.

Mulenga V, Cook A, Walker AS, Kabamba D, Chijoka C, Ferrier A, Kalengo C, Kityo C, Kankasa C, Burger D, Thomason M, Chintu C, Gibb DM. Mulenga V, et al. Clin Infect Dis. 2010 Nov 1;51(9):1081-9. doi: 10.1086/656628. Clin Infect Dis. 2010. PMID: 20868279 Clinical Trial.

4

Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.

Musiime V, Kendall L, Bakeera-Kitaka S, Snowden WB, Odongo F, Thomason M, Musoke P, Adkison K, Burger D, Mugyenyi P, Kekitiinwa A, Gibb DM, Walker AS; ARROW Trial team. Musiime V, et al. Antivir Ther. 2010;15(8):1115-24. doi: 10.3851/IMP1695. Antivir Ther. 2010. PMID: 21149918 Clinical Trial.

5

Low incidence of abacavir hypersensitivity reaction among African children initiating antiretroviral therapy.

Nahirya-Ntege P, Musiime V, Naidoo B, Bakeera-Kitaka S, Nathoo K, Munderi P, Mugyenyi P, Kekitiinwa A, Bwakura-Dangarembizi MF, Crawley J; ARROW Trial Team. Nahirya-Ntege P, et al. Pediatr Infect Dis J. 2011 Jun;30(6):535-7. doi: 10.1097/INF.0b013e3182076864. Pediatr Infect Dis J. 2011. PMID: 21164384 Clinical Trial.

6

Excellent adherence to antiretrovirals in HIV+ Zambian children is compromised by disrupted routine, HIV nondisclosure, and paradoxical income effects.

Haberer JE, Cook A, Walker AS, Ngambi M, Ferrier A, Mulenga V, Kityo C, Thomason M, Kabamba D, Chintu C, Gibb DM, Bangsberg DR. Haberer JE, et al. PLoS One. 2011 Apr 21;6(4):e18505. doi: 10.1371/journal.pone.0018505. PLoS One. 2011. PMID: 21533031 Free PMC article. Clinical Trial.

7

Mortality after fluid bolus in African children with severe infection.

Maitland K, Kiguli S, Opoka RO, Engoru C, Olupot-Olupot P, Akech SO, Nyeko R, Mtove G, Reyburn H, Lang T, Brent B, Evans JA, Tibenderana JK, Crawley J, Russell EC, Levin M, Babiker AG, Gibb DM; FEAST Trial Group. Maitland K, et al. N Engl J Med. 2011 Jun 30;364(26):2483-95. doi: 10.1056/NEJMoa1101549. Epub 2011 May 26. N Engl J Med. 2011. PMID: 21615299 Free article. Clinical Trial.

8

Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1.

Kasirye P, Kendall L, Adkison KK, Tumusiime C, Ssenyonga M, Bakeera-Kitaka S, Nahirya-Ntege P, Mhute T, Kekitiinwa A, Snowden W, Burger DM, Gibb DM, Walker AS; ARROW Trial Team. Kasirye P, et al. Clin Pharmacol Ther. 2012 Feb;91(2):272-80. doi: 10.1038/clpt.2011.225. Epub 2011 Dec 21. Clin Pharmacol Ther. 2012. PMID: 22190066

9

Young HIV-infected children and their adult caregivers prefer tablets to syrup antiretroviral medications in Africa.

Nahirya-Ntege P, Cook A, Vhembo T, Opilo W, Namuddu R, Katuramu R, Tezikyabbiri J, Naidoo-James B, Gibb D; ARROW Trial Team. Nahirya-Ntege P, et al. PLoS One. 2012;7(5):e36186. doi: 10.1371/journal.pone.0036186. Epub 2012 May 2. PLoS One. 2012. PMID: 22567139 Free PMC article.

10

Bacteremia, causative agents and antimicrobial susceptibility among HIV-1-infected children on antiretroviral therapy in Uganda and Zimbabwe.

Musiime V, Cook A, Bakeera-Kitaka S, Vhembo T, Lutakome J, Keishanyu R, Prendergast AJ, Lubwama S, Robertson V, Hughes P, Nathoo K, Munderi P, Klein N, Musoke P, Gibb DM; ARROW Trial Team. Musiime V, et al. Pediatr Infect Dis J. 2013 Aug;32(8):856-62. doi: 10.1097/INF.0b013e31828c3991. Pediatr Infect Dis J. 2013. PMID: 23407100 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

88 results

Search Page